| 徐 伟,何 艳,罗 涌,刘维娟,王 怡.利拉鲁肽联合二甲双胍对肥胖2型糖尿病患者糖脂代谢、血管内皮功能及微炎症状态的影响[J].,2021,(6):1107-1111 |
| 利拉鲁肽联合二甲双胍对肥胖2型糖尿病患者糖脂代谢、血管内皮功能及微炎症状态的影响 |
| The Effect of Lilaluptide Combined with Metformin on Glucose and Lipid Metabolism, Vascular Endothelial Function and Microinflammation in Obese Type 2 Diabetic Patients |
| 投稿时间：2020-05-23 修订日期：2020-06-18 |
| DOI：10.13241/j.cnki.pmb.2021.06.024 |
| 中文关键词: 利拉鲁肽 二甲双胍 肥胖2型糖尿病 糖脂代谢 内皮功能 微炎症状态 |
| 英文关键词: Lilalutide Metformin Obesity Type 2 diabetes Glucose and lipid metabolism Endothelial function Microinflammatory state |
| 基金项目:重庆市卫计委医学科研资助项目（2016MSXM0421） |
|
| 摘要点击次数: 876 |
| 全文下载次数: 510 |
| 中文摘要: |
| 摘要 目的：探讨利拉鲁肽联合二甲双胍对肥胖2型糖尿病（T2DM）患者糖脂代谢、血管内皮功能及微炎症状态的影响。方法：选取2016年7月~2019年4月期间我院收治的117例T2DM肥胖患者。根据随机数字表法分为对照组（n=58，二甲双胍治疗）和研究组（n=59，利拉鲁肽联合二甲双胍治疗），比较两组患者体质量指数（BMI）、糖脂代谢指标[高密度脂蛋白胆固醇（HDL-C）、空腹血糖（FPG）、甘油三酯（TG）、糖化血红蛋白（HbA1c）、低密度脂蛋白胆固醇（LDL-C）、总胆固醇（TC）]、血管内皮功能指标[内皮素（ET）、一氧化氮（NO）]及微炎症状态指标[C反应蛋白（CRP）、白介素-6（IL-6）以及肿瘤坏死因子-α（TNF-α）]，记录两组治疗期间不良反应情况。结果：治疗12周后，两组BMI、FPG及HbA1c、TG、TC、LDL-C、ET、CRP、TNF-α及IL-6均低于治疗前，且研究组低于对照组（P<0.05）。治疗12周后，两组HDL-C、NO高于治疗前，且研究组高于对照组（P<0.05）。两组不良反应发生率比较无差异（P>0.05）。结论：利拉鲁肽联合二甲双胍治疗肥胖T2DM患者，可有效控制其体内糖脂代谢紊乱，改善血管内皮功能及微炎症状态，且用药安全性较好。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the effect of lilaluptide combined with metformin on glucose and lipid metabolism, endothelial function and microinflammation in obese type 2 diabetes mellitus (T2DM). Methods: 117 obese T2DM patients who were admitted to our hospital from July 2016 to April 2019 were selected. According to the random number table method, the patients were divided into the control group (n=58, metformin treatment) and study group (n=59, lilalutide combined with metformin treatment). The body mass index (BMI), glucose and lipid metabolism indexes [high-density lipoprotein cholesterol (HDL-C), fasting plasma glucose (FPG), triglycerides (TG), glycosylated hemoglobin (HbA1c), low density lipoprotein cholesterol (LDL-C), total cholesterol (TC)], endothelial function indexes [endothelin (ET), nitric oxide (NO)] and micro inflammation state indexes [C-reactive protein (CRP) and interleukin 6 (IL-6) and tumor necrosis factor-α(TNF-α)] were compared between the two groups, the adverse reactions during the treatment were recorded. Results: 12 weeks after treatment, the BMI, FPG, HbA1c, TG, TC, LDL-C, ET, CRP, TNF-α and IL-6 of the two groups were lower than those before treatment, and those of the study group were lower than those of the control group(P<0.05). 12 weeks after treatment, HDL-C and NO of the two groups were higher than those before treatment, and those of the study group were higher than those of the control group (P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). Conclusion: Lilaluptide combined with metformin in the treatment of obese T2DM patients can effectively control the glucose and lipid metabolism, improve the vascular endothelial function and micro inflammatory state, and the drug safety is good. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
